You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-Objective Response Rates Presented for Both Antibody-Drug Conjugate Programs- -Enfortumab Vedotin Demonstrates 59 Percent Objective Response Rate at Recommended Phase 2 Dose of 1.25 mg/kg,...
NORTHBROOK, Ill., Oct. 5, 2016 /PRNewswire/ -- Astellas today announced the appointment of Steven E. Benner, M.D., as senior vice president and Therapeutic Area Head for Oncology, and the promotion of
Read more about Astellas Expands Leadership in Oncology Clinical Development
NORTHBROOK, Ill., Sept. 30, 2016 /PRNewswire/ -- Today, more than 600 Astellas employees on two continents will get out of their offices, roll up their sleeves and help their communities. This...
Astellas ranked for its commitment and support of working mothers NORTHBROOK, Ill., Sept. 28, 2016 /PRNewswire/ -- Astellas was named one of Working Mother Magazine's 100 Best Companies in the...
Follow U.S. news
